Allurion Technologies, Inc. Selling and Marketing Expense
Allurion Technologies, Inc. (ALUR) reported Selling and Marketing Expense of $1.30 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-05-15
- Allurion Technologies, Inc. selling and marketing expense for the quarter ending 2026-03-31 was $1.30M, a 63.99% decline year-over-year.
- Allurion Technologies, Inc. selling and marketing expense for the quarter ending 2025-12-31 was $1.64M, a 79.14% decline year-over-year.
- Allurion Technologies, Inc. selling and marketing expense for the quarter ending 2025-09-30 was $3.13M, a 39.79% decline year-over-year.
- Allurion Technologies, Inc. selling and marketing expense for the quarter ending 2025-06-30 was $2.41M, a 64.10% decline year-over-year.
- Allurion Technologies, Inc. selling and marketing expense for fiscal 2025 was $10.80M, a 58.34% decline from fiscal 2024.
- Allurion Technologies, Inc. selling and marketing expense for fiscal 2024 was $25.93M, a 44.66% decline from fiscal 2023.
- Allurion Technologies, Inc. selling and marketing expense for fiscal 2023 was $46.86M, a 7.04% decline from fiscal 2022.
- Allurion Technologies, Inc. selling and marketing expense for fiscal 2022 was $50.41M.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-03-31 | $1.30M 10-Q · filed 2026-05-15 | $2.95M derived: sum of 2 quarters · filed 2026-05-15 | $6.08M derived: sum of 3 quarters · filed 2026-05-15 | $8.49M derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $4.77M derived: sum of 2 quarters · filed 2026-03-30 | $7.18M derived: sum of 3 quarters · filed 2026-03-30 | $10.80M 10-K · filed 2026-03-30 |
| 2025-09-30 | $3.13M 10-Q · filed 2025-11-17 | $5.54M derived: sum of 2 quarters · filed 2025-11-17 | $9.16M 10-Q · filed 2025-11-17 | $17.04M derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-06-30 | $2.41M 10-Q · filed 2025-08-19 | $6.03M 10-Q · filed 2025-08-19 | $13.91M derived: sum of 3 quarters · filed 2026-05-15 | $19.10M derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-03-31 | $3.62M 10-Q · filed 2026-05-15 | $11.49M derived: sum of 2 quarters · filed 2026-05-15 | $16.69M derived: sum of 3 quarters · filed 2026-05-15 | $23.41M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $7.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $13.07M derived: sum of 2 quarters · filed 2026-03-30 | $19.79M derived: sum of 3 quarters · filed 2026-03-30 | $25.93M 10-K · filed 2026-03-30 |
| 2024-09-30 | $5.20M 10-Q · filed 2025-11-17 | $11.91M derived: sum of 2 quarters · filed 2025-11-17 | $18.06M 10-Q · filed 2025-11-17 | $28.79M derived: sum of 4 quarters · filed 2025-11-17 |
| 2024-06-30 | $6.72M 10-Q/A · filed 2025-08-28 | $12.86M 10-Q/A · filed 2025-08-28 | $23.59M derived: sum of 3 quarters · filed 2025-08-28 | $37.58M derived: sum of 4 quarters · filed 2025-08-28 |
| 2024-03-31 | $6.14M 10-Q/A · filed 2025-08-28 | $16.88M derived: sum of 2 quarters · filed 2025-08-28 | $30.86M derived: sum of 3 quarters · filed 2025-08-28 | $41.14M derived: sum of 4 quarters · filed 2025-08-28 |
| 2023-12-31 | $10.73M derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2025-08-28 | $24.72M derived: sum of 2 quarters · filed 2025-08-28 | $34.99M derived: sum of 3 quarters · filed 2025-08-28 | $46.86M 10-K/A · filed 2025-08-28 |
| 2023-09-30 | $13.99M 10-Q/A · filed 2025-08-28 | $24.26M derived: sum of 2 quarters · filed 2025-08-28 | $36.13M 10-Q/A · filed 2025-08-28 | $51.07M derived: sum of 4 quarters · filed 2025-08-28 |
| 2023-06-30 | $10.27M 10-Q/A · filed 2025-08-28 | $22.14M 10-Q/A · filed 2025-08-28 | $37.08M derived: sum of 3 quarters · filed 2025-08-28 | $52.76M derived: sum of 4 quarters · filed 2025-08-28 |
| 2023-03-31 | $11.86M 10-Q/A · filed 2025-08-28 | $26.80M derived: sum of 2 quarters · filed 2025-08-28 | $42.49M derived: sum of 3 quarters · filed 2025-08-28 | $53.40M derived: sum of 4 quarters · filed 2025-08-28 |
| 2022-12-31 | $14.94M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-08-28 | $30.63M derived: sum of 2 quarters · filed 2025-08-28 | $41.53M derived: sum of 3 quarters · filed 2025-08-28 | $50.41M 10-K/A · filed 2025-08-28 |
| 2022-09-30 | $15.69M 10-Q · filed 2023-11-14 | $26.59M derived: sum of 2 quarters · filed 2023-11-14 | $35.46M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $10.90M 10-Q · filed 2023-10-20 | $19.78M 10-Q · filed 2023-10-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Picard Medical, Inc. (PMI) | United States | $0.011B | -0.01 |
| NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) | United States | $0.012B | |
| Sintx Technologies, Inc. (SINT) | United States | $0.012B | -1.10 |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |
| CERENOME, INC. (CNSY) | United States | $0.014B | |
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| SeaStar Medical Holding Corp (ICU) | United States | $0.015B | -1.14 |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B |